Geoffrey Girnun is a seasoned biomedical researcher with a particular interest in cancer and its relationship to metabolism. Dr. Girnun's research focuses on how metabolic pathways implicated in obesity and diabetes are also critical actors in oncology. These research examined the underlying processes of cancer creation and progression, as well as the development of new therapies. Dr. Geoffrey Girnun got his bachelor's degree and doctorate from the University of Iowa, where he examined the relationship between essential fatty acids, which we now know are useful for maintaining healthy cells, and the enzymes in cells that defend against oxidative stress. He completed his postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, where he studied fundamental questions about cell development, discovered novel genes that protect against cancer, and developed therapeutic approaches for some of the most common and drug resistant cancers. Geoffrey Girnun created his own laboratory at the University of Maryland in Baltimore in 2007 and subsequently moved to Stony Brook University in 2013. Dr. Geoffrey Girnun produced groundbreaking discoveries during that time period, establishing a relationship between metabolic pathways and cancer. Additionally, he established proof-of-concept therapy techniques that specifically target these circuits. Dr. Girnun has also worked as a consultant for venture capital firms, hedge funds, small biotech and major pharmaceutical businesses. He is passionate about reading, the outdoors, exercising, and spending time with friends and family.